Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting Apr 4, 2022
Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference Dec 15, 2021
Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer Nov 22, 2021
Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα) Sep 17, 2021
Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha Jul 19, 2021
Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board Apr 29, 2021
Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting Mar 29, 2021
